MAIA Biotechnology
MAIA
12 hedge funds and large institutions have $709K invested in MAIA Biotechnology in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
187% more capital invested
Capital invested by funds: $247K → $709K (+$462K)
100% more funds holding
Funds holding: 6 → 12 (+6)
1.71% more ownership
Funds ownership: 0.65% → 2.36% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$250K |
| 2 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$93.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$90.9K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$71.2K |
| 5 |
CWM
Centric Wealth Management
Chicago,
Illinois
|
+$64.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$26.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$13.7K |
MAIA Hedge Fund Activity: Q2 2023 in Review
12 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q2 2023, worth a combined $709K — up 187% from $247K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MAIA positions and 1 closed out — a net gain of 6 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $250K. The largest seller was Renaissance Technologies, cutting an estimated $26.3K.
- 12 institutional investors held MAIA Biotechnology (MAIA) as of Q2 2023, up from 6 in Q1 2023.
- Funds reported $709K of MAIA Biotechnology stock for Q2 2023, up 187% quarter-over-quarter.
- 7 funds opened new MAIA Biotechnology positions in Q2 2023 and 1 closed out, a net change of +6 holders.
- The largest MAIA Biotechnology buyer in Q2 2023 was Vanguard Group, an estimated $250K added.
- The largest MAIA Biotechnology seller in Q2 2023 was Renaissance Technologies, an estimated $26.3K sold.
Based on aggregated 13F filings for Q2 2023.